Key points are not available for this paper at this time.
Dysfunctional adipose tissue contributes to several diseases, including diabetes, cardiovascular disease, and some cancers. Among the global female population, breast cancer is a cancer type that is increasing gradually in annual cases, while it also has the highest mortality rate. Recent evidence indicates that accumulation of the adipose tissue mass contributes to the progression of breast cancer proliferation and metastasis. The purposes of this study are to investigate the effects of pinostrobin - a compound extracted from Boesenbergia rotunda (L.) - on 3T3-L1 preadipocyte differentiation and migration as well as its inhibitory effects on adipocyte-induced MCF-7 proliferation and migration. This study revealed that pinostrobin at a concentration of 0 to 25 µM was not toxic to the 3T3-L1 cells and treatment with 25 µM pinostrobin dramatically reduced the adipogenesis of 3T3-L1 compared to untreated cells, as measured by both Oil Red O and Nile red fluorescence staining. In addition, the migratory ability of 3T3-L1 was reduced at 6 h post-treatment measured by wound healing migration assay. An indirect co-culture system of MCF-7 and an adipocyte-conditioned medium revealed a further increase in the ability of the MCF-7 to migrate and proliferate. Interestingly, treatment with pinostrobin at a concentration of 25 µM could suppress cell migration and inhibit the colony formation of MCF-7 breast cancer cells in the context of this co-culture system. Based on the findings of this study, pinostrobin could be a promising therapeutic candidate as a novel cancer treatment drug used in patients with obesity-related breast cancer in the future. HIGHLIGHTS Pinostrobin extracted from Boesenbergia rotunda (L.) inhibits breast cancer cell proliferation and migration in an indirect co-culture system of adipocytes and MCF-7 cells. Pinostrobin significantly suppresses 3T3-L1 adipocyte differentiation and migration. GRAPHICAL ABSTRACT
Benchamana et al. (Tue,) studied this question.